|
|
Blood, 1 March 2006, Vol. 107, No. 5, pp. 1751-1760.
Prepublished online as a Blood First Edition Paper on November 3, 2005; DOI 10.1182/blood-2005-06-2335.
 Previous Article | Table of Contents | Next Article 
REVIEW ARTICLES
Survival of the fittest: in vivo selection and stem cell gene therapy
Tobias Neff,
Brian C. Beard, and
Hans-Peter Kiem
From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and the University of Washington School of Medicine, Seattle.
Stem cell gene therapy has long been limited by low gene transfer efficiency to hematopoietic stem cells. Recent years have witnessed clinical success in select diseases such as X-linked severe combined immunodeficiency (SCID) and ADA deficiency. Arguably, the single most important factor responsible for the increased efficacy of these recent protocols is the fact that the genetic correction provided a selective in vivo survival advantage. Since, for most diseases, there will be no selective advantage of gene-corrected cells, there has been a significant effort to arm vectors with a survival advantage. Two-gene vectors can be used to introduce the therapeutic gene and a selectable marker gene. Efficient in vivo selection strategies have been demonstrated in clinically relevant large-animal models. Mutant forms of the DNA repair-enzyme methylguanine methyltransferase in particular have allowed for efficient in vivo selection and have achieved sustained marking with virtually 100% gene-modified cells in large animals, and with clinically acceptable toxicity. Translation of these strategies to the clinical setting is imminent. Here, we review how in vivo selection strategies can be used to make stem cell gene therapy applicable to the treatment of a wider scope of genetic diseases and patients.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. C. Beard, R. Sud, K. A. Keyser, C. Ironside, T. Neff, S. Gerull, G. D. Trobridge, and H.-P. Kiem
Long-term polyclonal and multilineage engraftment of methylguanine methyltransferase P140K gene-modified dog hematopoietic cells in primary and secondary recipients
Blood,
May 21, 2009;
113(21):
5094 - 5103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. J. Lee, P. Kahatapitiya, B. Kramer, J. E. Joya, J. Hook, R. Liu, G. Schevzov, I. E. Alexander, G. McCowage, D. Montarras, et al.
Methylguanine DNA Methyltransferase-Mediated Drug Resistance-Based Selective Enrichment and Engraftment of Transplanted Stem Cells in Skeletal Muscle
Stem Cells,
May 1, 2009;
27(5):
1098 - 1108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. C. Porter and J. DeGregori
Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection
Blood,
December 1, 2008;
112(12):
4466 - 4474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-B. Zhang, J. L. Schwartz, R. K. Humphries, and H.-P. Kiem
Effects of HOXB4 Overexpression on Ex Vivo Expansion and Immortalization of Hematopoietic Cells from Different Species
Stem Cells,
August 1, 2007;
25(8):
2074 - 2081.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hsu, S. A. Jones, C. J. Cohen, Z. Zheng, K. Kerstann, J. Zhou, P. F. Robbins, P. D. Peng, X. Shen, T. J. Gomes, et al.
Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene
Blood,
June 15, 2007;
109(12):
5168 - 5177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Barese, N. Pech, S. Dirscherl, J. L. Meyers, A. L. Sinn, M. C. Yoder, W. S. Goebel, and M. C. Dinauer
Granulocyte Colony-Stimulating Factor Prior to Nonmyeloablative Irradiation Decreases Murine Host Hematopoietic Stem Cell Function and Increases Engraftment of Donor Marrow Cells
Stem Cells,
June 1, 2007;
25(6):
1578 - 1585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
